HC Wainwright Predicts Lower Earnings for Spero Therapeutics

Spero Therapeutics, Inc. (NASDAQ:SPRO) – Research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for shares of Spero Therapeutics in a research note issued to investors on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($1.23) for the year, down from their previous estimate of ($0.75). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.29) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q4 2024 earnings at ($0.35) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.84) EPS.

A number of other equities analysts have also commented on SPRO. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th.

Spero Therapeutics Price Performance

Spero Therapeutics stock opened at $1.16 on Wednesday. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $1.32. Spero Therapeutics has a one year low of $1.01 and a one year high of $1.89. The firm has a market cap of $63.24 million, a PE ratio of 16.57 and a beta of 0.59.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SPRO. Vanguard Group Inc. lifted its stake in shares of Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the period. Virtu Financial LLC bought a new stake in Spero Therapeutics during the 1st quarter worth approximately $31,000. Acadian Asset Management LLC increased its holdings in Spero Therapeutics by 40.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after purchasing an additional 309,262 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock valued at $1,269,000 after acquiring an additional 121,492 shares in the last quarter. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.